Ignite Creation Date:
2024-05-06 @ 7:08 PM
Last Modification Date:
2024-10-26 @ 3:01 PM
Study NCT ID:
NCT05905614
Status:
COMPLETED
Last Update Posted:
2024-06-17
First Post:
2023-05-29
Brief Title:
Phase I Clinical Study of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Sponsor:
Shanghai Pharmaceuticals Holding Co Ltd
Organization:
Shanghai Pharmaceuticals Holding Co Ltd
Study Overview
Official Title:
An Open-label Dose-escalation Phase I Clinical Trial to Explore the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of SPH4336 Tablets in the Treatment of Advanced Solid Tumors
Status:
COMPLETED
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This clinical study evaluated the safety and efficacy of SPH4336 in the treatment of advanced solid tumors
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None